T
HE prognosis for patients with malignant gliomas treated with the currently available modalities of surgery, radiotherapy, and chemotherapy remains poor. Further improvements in patient survival may depend upon a deeper understanding of the growth factor pathways that regulate glioma proliferation. During the last several years, increasing interest has been focused on the role of various polypeptide growth factors such as epidermal growth factor (EGF), 6A8' 62 platelet-derived growth factor (PDGF), s56~ the fibroblast growth factors (FGF's), ~6 and the insulin-like growth factors (IGF's)/4 as well as the role of protein kinase Cmediated pathways ~4243 in the growth of malignant gliomas.
Several lines of evidence support the involvement of these polypeptide mitogens and protein kinase C in glioma proliferation. First, amplification and possible rearrangement of the EGF receptor gene, ~ 1,33.73 increased transcription of EGF receptor messenger ribonucleic acid (mRNA)/~,24,33,73 and enhanced EGF receptor expression ~346667 have been found in some malignant glioma specimens. Second, the observation that many malignant glial lines not only have receptors for PDGF, -~-~3 but also may express the cellular oncogene that codes Definitions of Abbreviations = bovine serum albumin = epidermal growth factor = fetal calf serum = fibroblast growth factor = acidic FGF = basic FGF = glial fibrillary acidic protein = Hanks" balanced salt solution = insulin-like growth factor = nerve growth factor = phosphate-buffered saline = platelet-derived growth factor = trichloroacetic acid = 12-O-tetradecanoyl-13 phorbol acetate for PDGF ~,m2~ and synthesize and secrete a PDGF-like mitogenic factor -''~~44:4s suggests the occurrence of autocrine stimulation. 6~j Third, glial tumors are known to synthesize FGF ~ and IGF -'~52 and to have receptors for these hormones, ~''4 ._~,_,~ ~ suggesting the presence of multiple autocrine loops. Finally, EGF, 2-~:3-'4~ PDGF, 46 .3. _~<7_~ IGF, Lg.3L,3~ FGF]O and the protein kinase C-activating phorbol ester, 12-0-tetradecanoyl-13-phorbol acetate (TPA), <-75 have each been shown to lead to a pronounced mflogenic response in fetal and neonatal astrocytes, indicating that immature glia possess the capacity to respond to these hormones.
Since it has been reported that none of these agents is mitogenic in normal adult glia, 7~ this responsiveness is apparently lost during maturation but may be reacquired in neoplastic glia as these cells assume an undifferentiated phenotype. However, direct evidence supporting a role for one or more of these growth factor pathways in glioma proliferation has been presented in only a handful of reports. 7' 1 i.t3,15.66,fi9 To address this issue in detail, we examined the effect of various mitogens, neutralizing antibodies directed against selected growth factors, and inhibitors of growth factor-mediated pathways on deoxyribonucleic acid (DNA) synthesis and cell division of low-passage human glioma lines grown in a chemically defined medium.
Materials and Methods

Cell Culture
Cultures of human malignant glial cells were derived from freshly obtained surgical specimens. The histological diagnosis of the tumors used was glioblastoma multiforme. Tumor tissue was finely minced, passed through 100-#m nylon mesh, and plated in modified Eagle's medium supplemented with Earle's salts, trace elements, and 10% fetal calf serum (FCS), and with the following antibiotics: penicillin G, 80 U/ml; streptomycin, 80 ug/ml; and fungizone, 0.20 ug/ml. Cells were maintained at 37~ in a humidified atmosphere with 5% CO~ in air. After reaching confluence, the cells were treated with 0.25% tUpsin in Hank's balanced salt solution (HBSS) and subcultured for immunohistochemical and growth factor studies. All studies were performed on cells in their second to fourth passages.
lmmunohistochernical Examination
lmmunohistochemical staining for glial fibrillary acidic protein (GFAP) was performed to confirm the glial nature of the cultured lines. Cells were plated onto glass slides, at 5 x 104 cells/slide, in the above serumsupplemented medium and, on the 3rd day after seeding, were fixed with ice-cold 70% ethanol for 1 hour. The cells were then washed in phosphate-buffered saline (PBS), rendered permeable by treatment with 0.1% Triton-X in PBS for 10 minutes, washed again, and incubated for 1 hour in 10% horse serum/PBS to minimize nonspecific binding of the primary antibody. The monolaycr was then incubated with a rabbit polyclonal antibody to GFAP, s 1:I000 dilution in 10% horse serum/PBS, for 2 hours at room temperature. Control cells were incubated with horse serum/PBS alone. After extensive washing in PBS, cells were labeled using a horseradish peroxidase-conjugated avidin-biotin peroxidase complex kit.* Antibody binding was detected using an intensified diaminobenzidine reactionY Each of the four lines used in this study had greater than 98% GFAP-positive cells.
Measurement of Growth Factor-Induced DNA Synthesis
Cells were seeded onto 96-well round-bottomed microtiter trays (2 x 104 cells in 200 ~1 of serum-supplemented medium/well), and after a 6-hour attachment period, were washed three times in serum-free MCDB 105 medium :~v with antibiotics and grown for 24 hours under serum-free conditions. This medium has been previously shown to maintain the viability of malignant glial cells for up to 7 days in culture. ~~ Cells were then incubated for 24 hours with the various concentrations of the following mitogens in MCDB 105 with 0.1% bovine serum albumin (BSA): EGF (0.1 to 50 ng/mL), acidic FGF (0.l to 50 ng/ml), basic FGF (0.1 to 50 ng/ml), IGF factor I (IGF-I, 1 to 200 ng/ml), nerve growth factor (NGF, 1 to 500 ng/ml), PDGF B chain dimer (1 to 200 ng/ml), TPA (0.1 to 50 ng/ml), or FCS (1% and 10%). Control cells were incubated without exogenous mitogens in MCDB with BSA. All studies were performed in triplicate. Cells were then washed and incubated for 4 hours in serum-free medium with [~H]-thymidine (I uCi/ml). After extensive washing to remove unbound radioactivity, cells were detached by a 30-minute incubation at room temperature in 2.5% trypsin/0.85% NaCI and centrifuged for 20 minutes at 2000 G. The pellet was suspended in 6% FIG. 1. [~H]-thymidine incorporation in four human malignant gliomas (F.M., R.E., L.C., and E.S.) in response to growth factors and serum. Concentrations of growth factors shown are: EGF, 10 ng/ml; FGF(a), 1 ng/ml; FGF(b), 1 ng/ml~ IGF, 50 ng/ml; NGF, 100 ng/ml; PDGF, 50 ng/ml; and TPA, 10 ng/ml (see Definitions of Abbreviations table). Significant difference from control, unpaired Student's t-test: * = p < 0.05; 9 * = p < 0.01; *** = p < 0.001. trichloroacetic acid (TCA) and 0.03% unlabeled thymidine. Following a 30-minute incubation period, the acid precipitate was centrifuged; the pellet was then suspended and incubated in fresh TCA solution, and centrifuged again. The precipitate was solubilized in 200 ul of 0.5 N NaOH with 0.1% BSA, transferred to scintillation vials, and mixed with 5 ml of Ecolite scintillation cocktail.t Incorporated radioactivity was measured in a beta scintillation counter.
Proliferative Response to Added Growth Factors
Cells from three of the tumors (LC, ES, and RE) were seeded into 35-ram Petri plates (5 • 104 cells/ plate) in serum-supplemented medium, and after a 6-hour attachment period, were grown under serum-free conditions (MCDB 105 with 0.1% BSA) for 24 hours. (The fourth tumor did not survive long enough in culture for these studies to be performed.) Cell counts were rechecked 24 hours after plating to determine the total number of cells present before the addition of growth factors. Growth factors or serum were then added, and the cells were grown for an additional 96 hours. Control cells received no growth factors or serum. All studies were performed in triplicate. Cells were then detached with 0.25% trypsin in HBSS and counted in a hemacytometer.
Effect of Growlh Factor Antibodies and Inhibitors
To examine the effect of selective blockade of growth factor-mediated pathways on control (no added growth factors) and PDGF-and serum-stimulated DNA synthesis in the LC, ES, and RE tumors, we repeated the [3H]-thymidine incorporation studies in the presence of the following neutralizing antibodies to various growth factors and inhibitors of selected growth-mediated pathways: 1) anti-EGF, 2) anti-PDGF, 3) anti-acidic FGF, 4) anti-basic FGF, 5) anti-NGF, 6) trapidil (5-methyl-7-diethylamino-s-triazol [l,5a] pyrimidine),z~ an inhibitor of PDGF, ~~ and 7) polymyxin B, an inhibitor of protein kinase C activation. 2~3664727476 Anti-growth t Ecolite scintillation cocktail manufactured by ICN Biomedicals, Cleveland, Ohio. factor antibodies were used at concentrations of 2.5, 10, or 4(1 ug/ml; 10 to 40 gg/ml of each has previously been found to inhibit by more than 90% the responses to exogenous administration of optimal concentrations of their respective growth factors in the EGF-, PDGF-, and FGF-responsive T98G malignant glioma line 6~ (data not shown). In this cell line, the anti-PDGF antibody blocked the effects of both recombinant B chain homodimeric PDGF and platelet-derived (presumably A-B heterodimeric) PDGF. Trapidil was used at concentrations of l0 and 100 ng/ml, and 1, 10, and 100 #g/ml. Polymyxin B was used at concentrations of 1, 5, 10, 20, and 50 ug/ml. Cell proliferation studies in control and PDGF-and serum-stimulated cells from the LC, ES, and RE gliomas were also performed in the presence of selected concentrations of the above inhibitors.
Results
The responses of the four human gliomas to optimum concentrations of the different growth factors and to serum are shown in Fig. 1 . Platelet-derived growth factor produced a significant enhancement of DNA synthesis (p < 0.05, unpaired Student's t-test) in all four tumors, with maximum effects at 50 ng/ml. Three tumors showed a significant dose-dependent response to EGF, three to IGF-I, two to acidic FGF, two to basic FGF, and two to TPA, with maximum effects at 10, 50, 1, 1, and 10 ng/ml, respectively. None of the tumors responded to NGF. In the responsive tumors, optimum concentrations of EGF, IGF, TPA, and FGF induced a two-to fourfold increase in [3H]-thymidine incorporation, which was only 30% to 50% of the response seen in 10% serum. In contrast, PDGF increased DNA synthesis eight-to 10-fold over control, generally approximating the effect of 10% serum. The doseresponse curves for each of the tumors to PDGF are illustrated in Fig. 2 .
Studies of cell proliferation in each of the three tumors tested confirmed the pronounced mitogenic effect of PDGF (Fig. 3) . Whereas control cells increased in number by 10% to 74% in the absence of added growth factors, cells treated with PDGF demonstrated a 110% to 230% increase in number. In each of the tumors, the response to PDGF approximated that seen with 10% serum. Epidermal growth factor also produced a significant increase in cell number over control levels in each of the three tumors, but the magnitude of the response was much smaller than that obtained with PDGF. The responses to the other mitogens varied among the different cell lines and, in general, were comparatively small.
As expected, the anti-PDGF neutralizing antibody strongly inhibited DNA synthesis and proliferation induced by exogenously administered PDGF (data not shown). In addition, this antibody significantly inhibited baseline DNA synthesis (Fig. 4) and cell proliferation (Fig. 5 ) in cells not receiving exogenous growth factors or serum. However, it only slightly inhibited the effect of serum on DNA synthesis (Fig. 6 ) and cell proliferation (Fig. 7) . Although the degree of inhibition was statistically significant in each of the lines tested, both DNA synthesis and cell proliferation remained well above control levels even in the presence of high concentrations with anti-PDGF antibody. In contrast, the other neutralizing antibodies produced no consistent inhibitory effect on either baseline or serum-stimulated DNA synthesis or proliferation (data not shown).
In cells exposed to trapidil or polymyxin B, PDGFstimulated DNA synthesis was significantly inhibited by concentrations of 1 to 100 u/ml and 10 to 50 ug/ ml, respectively. Trapidil and polymyxin B also produced a dose-dependent inhibition of baseline (Figs. 4 and 5) and serum-stimulated (Figs. 6 and 7) DNA synthesis and cell proliferation.
FIG. 4.
Effect of an anti-platelet-derived growth factor antibody (PDGF Ab), polymyxin B (PMB), and trapidil (Trap.) on baseline DNA synthesis in three human malignant gliomas (L.C., R.E., and E.S.).
Discussion
Effect of P D G F on Low-Passage Tumor Lines
The data presented here suggest that PDGF is a dominant mitogen for low-passage human malignant gliomas in vitro. Platelet-derived growth factor causes a substantial enhancement of both DNA synthesis and cell proliferation which, at optimum concentrations, approximates the response obtained with 10% serum. A similar effect of PDGF on the proliferation of lowpassage cultures of malignant glial tumors has recently been noted by Frappaz, et al., ~~ and Westphal, et alp 9 Other evidence supporting a major role for PDGF in glioma proliferation is provided by the observations of several groups that gliomas not only possess receptors for PDGF, but also secrete a PDGF-Iike mitogenic factor, 4"2~ creating a potential PDGF-mediated FIG. 5. Effect of an anti-platelet-derived growth factor antibody (PDGF Ab), polymyxin B (PMB), and trapidil (Trap.) on baseline cell preliferation in lhree human malignant gliomas (L.C., R.E., and E.S.).
FIG. 6.
Effect of an anti-plalelet-derived growth factor antibody (PDGF Ab), polymyxin B (PMB), and trapidil (Trap.) on serum-induced DNA synthesis in three human malignant gliomas (L.C., R.E., and E.S.). autocrine loop. Our finding that both an antibody against PDGF and trapidil, an agent reported to inhibit the action of PDGF, ~c~47'4~ inhibited proliferation of control cells is consistent with the hypothesis that a PDGF-mediated autocrine loop does indeed contribute to the basal mitotic rate we observed in our cells when they were maintained in a serum-and growth factorfree environment.
It remains uncertain whether the A-A, B-B, or A-B chain forms of PDGF are responsible for this autocrine stimulation since glioma-derived cell lines are known to express mRNA encoding both the A and B chains of PDGF. 2e Since all three forms of PDGF may activate glioma PDGF receptors, more selective inhibitors targeted individually at the A-A, B-B, and A-B chain dimers are needed to elucidate their relative contributions to the autocrine growth stimulation. Furthermore, it remains uncertain whether the autocrine activation in these tumors occurs strictly extracellularly or both extracellulafly and intracellularly. Huang, et al., ~-~ reported that in simian sarcoma virus-transformed NRK and NIH 3T3 cells, which secrete p28*% a transforming protein homologous to the PDGF B chain, [SH]-thymidine incorporation was inhibited (but not eliminated) by the administration of an anti-PDGF antibody. This suggests that some of the autocrine stimulation in these cell lines resulted from interaction of p28 T M with cell-surface receptors. However, other studies have indicated that the major component of autocrine activation in some lines may occur intracellularly) ~ Our finding that baseline DNA synthesis and cell proliferation in three human glioma lines was largely, but not totally, eliminated by the PDGF anti-FIG. 7. Effect of an anti-platelet-derived growth factor antibody (PDGF Ab), polymyxin B (PMB), and trapidil (Trap.) on serum-induced cell proliferation in three human malignant gliomas (L.C., R.E., and E.S.). body suggests that in these tumors a significant component of the autocrine activation occurs by extracellular interaction of PDGF with its receptor; however, it leaves open the possibility that intracellular activation may also be occurring.
The Effect of lnhibition of PDGF Pathways
Although PDGF appears to play a major role in controlling glioma proliferation in a chemically defined medium, our finding that serum-induced DNA synthesis and proliferation was only slightly affected by the anti-PDGF antibody indicates that other components of serum also modulate glioma growth. Other investigators have shown that EGF, ~ ~.~.~6,~ FGF,7,~ and IGF ~-s are all mitogens for certain human gliomas in vitro. Although the responses to these other agents varied I. F. Pollack, et al. among the four tumors examined in this study and exerted, at best, only a fraction of the effect noted with PDGF, the composite effect of the different growthstimulating constituents of serum is apparently sufficient to support an intense mitogenic response in the absence of PDGF. The fact that trapidil was able to strongly inhibit both baseline and serum-stimulated DNA synthesis and proliferation indicates that the inhibition of mitogenesis caused by this agent involves more than the PDGF-mediated pathways.
The Role of Protein Kinase C
Our finding that the protein kinase C inhibitor, polymyxin B, produced a significant dose-dependent inhibition of control, as well as PDGF-and serum-stimulated DNA synthesis and proliferation, suggests that protein kinase C-mediated pathways are involved in the proliferation of these low-passage tumors. This is in agreement with our previous work on established human glioma lines, 4~ in which we found a pronounced, reversible cytostatic effect of polymyxin B (with no alteration of cell viability, as assessed by trypan blue exclusion). Although it cannot be established with certainty that the inhibitory effects of polymyxin B are due solely to its effect on protein kinase C, the concentrations used in this study have been shown to produce fairly selective inhibition of protein kinase C with little effect on the protein kinases sensitive to circulating adenosine monophosphate, circulating glucose monophosphate, or calmodulin) 674 and have been found to inhibit other protein kinase C-dependent processes in cultured cells. 29"3&64"72'74"7~' Although two of the tumors inhibited by polymyxin B did not show a significant response to direct activation of protein kinase C by the phorbol ester TPA, it is conceivable that protein kinase C-mediated pathways may be involved indirectly as a part of the mitogenic signal initiated by the binding of other growth factors such as PDGF and EGF to their respective receptors. In this regard, both EGF and PDGF are known to induce tyrosine phosphorylation of phospholipase C ~5' 3~6~ and to stimulate phospholipase C activity; '5 this leads to enhanced turnover of phosphatidy[inositol and increased production of diacylglycerol, f7'5~:7 an endogenous ligand for the protein kinase C receptor. It has therefore been suggested that the mitogenic effects of agents such as PDGF may result, in part, from protein kinase C-mediated phosphorylation of appropriate substrates. 2w;
Conclusions
Human glioblastoma cell lines in culture show a consistent and dramatic mitogenic response to PDGF. Although these tumors also responded to a number of other growth factors, the magnitude of the responses was comparatively small and the pattern of responsiveness varied significantly among different gliomas. In addition, our glioma lines were able to proliferate in vitro in the absence of exogenous growth factors or serum, probably because of autocrine stimulation by mitogens such as PDGF. Unfortunately from a therapeutic standpoint, the selective blockade of the binding of a single growth factor, such as PDGF, to its receptor may not prove useful for inhibiting glioma growth in vivo, given that the effect of serum could not be inhibited completely by any one of the anti-growth factor antibodies tested. Other strategies that capitalize on the presence of high numbers of certain growth factor receptors on malignant gliomas, such as the use of toxin-or radionuclide-conjugated ligands, ' may be more useful. An encouraging observation is the finding that inhibition of protein kinase C appears to strongly inhibit baseline as well as growth factor-and seruminduced DNA synthesis and cell proliferation. It remains to be seen whether protein kinase C inhibition will prove clinically effective, without unacceptable levels of toxicity. 
